Key Drivers
- Strong liquidity
- Negative cash flow
- Weak efficiency
AIAI Summary
OPK now looks less like a pure cash-burning healthcare conglomerate and more like a multi-optionity turnaround, but the investable thesis still depends on one of its early pipeline or China RAYALDEE bets producing real clinical/commercial proof before ongoing negative cash flow erodes value.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Negative cash flow
- •Weak efficiency
OPK has solid near-term liquidity and moderate leverage, but persistent losses, negative cash flow, and weak asset efficiency make the stock look financially resilient yet fundamentally challenged.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Support holding
- •Resistance cap
OPK has been in a constructive uptrend over the last month, holding higher lows and support around $1.43-$1.46, but repeated stalls near $1.53 make near-term upside look capped for now.
The move from $1.39 to $1.53 has repeatedly stalled near resistance, suggesting a short-term pause or pullback risk
Sentiment & News
Key News Insights:
- •Preclinical progress
- •Conference visibility
- •Early-stage program
OPK's only notable update was the preclinical ENDO 2026 presentation of OPK8801001, signaling ongoing early-stage development of a long-acting hGH receptor antagonist for acromegaly.
This is a modest, neutral-positive catalyst that adds visibility to OPK's pipeline but does not yet change the investment case without clinical or regulatory data
Similar Companies in Healthcare
Other companies in the same sector with AI ratings